Comparator Sourcing

Comparator sourcing is the process of identifying, procuring, and managing supply of an active comparator — an already-approved medication used as the control-arm treatment in a clinical trial — as opposed to, or alongside, a placebo. It covers everything from locating a licensed source for the comparator product through blinding it to match the investigational product’s appearance, verifying its authenticity and chain of custody, and meeting the regulatory requirements that apply to any product dispensed under a trial protocol.

A trial requires comparator sourcing whenever its protocol specifies an active-controlled or active-comparator design rather than a placebo-only control arm — for example, testing a new therapy against the current standard of care. See Randomized Controlled Trial (RCT) for how control-arm choice fits into overall trial design, and Placebo-Controlled Study Design for when an active comparator is used instead of, or in addition to, placebo (common where withholding effective treatment would be unethical).

Why sponsors source an active comparator

Regulators and research-ethics bodies generally expect a trial to compare a new intervention against the best available standard of care rather than placebo when an effective standard treatment already exists for the condition under study — a principle reflected in ICH guidance on choice of control group (ICH E10) and in research-ethics review generally. That makes active-comparator designs common in oncology, cardiovascular disease, and other areas with an established standard of care, and it makes the sponsor responsible for supplying a product it did not manufacture, which is where sourcing becomes its own operational discipline distinct from investigational-product manufacturing.

Core sourcing challenges

Supply-chain integrity and authenticity verification

Because the comparator is typically purchased on the open commercial market rather than manufactured in-house, sponsors and their sourcing vendors must establish a documented chain of custody back to an authorized manufacturer or distributor — sometimes called product “pedigree” — to rule out counterfeit, diverted, or substandard product entering the trial. This is a materially different risk profile than sourcing the sponsor’s own investigational product, and it is the reason specialist comparator-sourcing vendors and depots exist alongside standard clinical-supply logistics.

Regional availability and formulation differences

The same branded or generic product can be manufactured differently, carry different approved indications, or simply not be marketed at all across the countries a multi-region trial enrolls in, forcing sponsors to either source locally per country or import a single global batch under the destination country’s import-license requirements — each path with its own cost, timeline, and regulatory tradeoffs.

Resupply continuity

Unlike investigational product, which the sponsor controls end-to-end, comparator resupply depends on a third-party market the sponsor doesn’t control for pricing, discontinuation, or shortages, so sourcing plans typically build in buffer stock and multiple qualified suppliers to avoid a resupply gap interrupting dosing partway through the trial.

Blinding the comparator

When the protocol is blinded (see Blinding/Masking in Clinical Trials), the comparator’s physical appearance — tablet size, color, shape, packaging — must be indistinguishable from the investigational product to the patient, and often the investigator and site staff as well. The most widely used technique for this is over-encapsulation: placing the commercial comparator tablet or capsule inside an opaque capsule shell, backfilled with an inert excipient (commonly microcrystalline cellulose or lactose monohydrate) to prevent rattling, so the outer shell looks identical regardless of what’s inside. Over-encapsulation avoids having to manufacture a separate matching placebo formulation of the comparator from scratch, but it introduces its own technical questions — encapsulation can measurably alter a tablet’s disintegration and dissolution behavior versus the original licensed formulation, so sponsors typically need dissolution/bioequivalence data on the over-encapsulated product, not just the original.

Regulatory requirements for handling comparators

An active comparator sourced for a trial is generally treated as an investigational medicinal product for regulatory purposes once it enters the study — see Investigational Medicinal Product (IMP). In practice this means:

• Manufacturing/repackaging oversight. Any re-packaging, re-labeling, or over-encapsulation of a comparator must itself be performed under Good Manufacturing Practice — in the EU, this falls under GMP Annex 13 (manufacture of investigational medicinal products); in the US, under 21 CFR Part 211.
• Labeling. Comparator packaging distributed for a US trial must carry the same investigational-use caution statement required of any IMP under 21 CFR 312.6, and EU trials have equivalent IMP-labeling requirements under the EU Clinical Trials Regulation.
• Distribution and import. Cross-border movement of the comparator into a trial site is subject to Good Distribution Practice and the destination country’s import-license/customs requirements for medicinal products, on top of whatever authorization applies to the comparator in its country of origin.
• Chain-of-custody and pharmacy handling. Once on-site, the comparator is dispensed and accounted for through the same investigational-product control processes as the sponsor’s own product — see Research Pharmacy — including temperature-controlled storage, dispensing logs, and drug accountability records.

Worked example

A sponsor running a Phase 3 oncology trial against the current standard-of-care chemotherapy needs the comparator available at 40 sites across 8 countries. Because the branded product is marketed under different trade names and pack sizes in each region, the sponsor engages a specialist comparator-sourcing vendor to source locally in each country rather than shipping a single global batch, over-encapsulates the tablets centrally to match the investigational product’s capsule appearance, and requires each shipment to carry full chain-of-custody documentation from an authorized wholesaler before it is released to the depot.

Counter-example

A trial comparing an investigational drug against placebo alone, with no active standard-of-care arm, does not involve comparator sourcing in this sense — the placebo is manufactured to match the investigational product directly rather than procured on the open market, so none of the sourcing, pedigree, or third-party-supply challenges described above apply. See Placebo-Controlled Study Design.

Related terms

• Randomized Controlled Trial (RCT)
• Blinding/Masking in Clinical Trials
• Placebo-Controlled Study Design
• Investigational Medicinal Product (IMP)
• Research Pharmacy
• Clinical Trial Supply Management (guide)